Articles tagged with Vascular Endothelial Growth Factor
Scientists have developed a method to deliver growth factor to regrow blood vessels, which could lead to revolutionary heart disease treatment. The research, published in PNAS, uses a novel delivery system that increases the activity and stability of growth factor.
A novel nanostructure mimics vascular endothelial growth factor to promote blood vessel growth, potentially treating conditions like peripheral arterial disease. The nanostructure shows promise in restoring blood flow and has a longer half-life compared to the natural protein, enhancing its potency.
Researchers at URMC discovered a receptor called GPR56 that plays an important role in cancer progression and may trigger angiogenesis. This discovery could lead to more effective treatments for malignant melanoma by shutting down VEGF production at its source.
Dr. Napoleone Ferrara has made significant contributions to the understanding of angiogenesis, a process that plays a key role in cancer proliferation and various diseases. His research led to the development of new treatments for age-related macular degeneration and cancer.
Researchers found that higher levels of perceived stress and depressive symptoms are associated with greater VEGF expression in tumor tissue, leading to shorter disease-free survival. The study suggests psychosocial interventions may have limited impact on patients with advanced cancer.
Researchers developed two peptide inhibitors targeting HER-2 and VEGF pathways, showing additive benefits in reducing tumor burdens with minimal side effects. The strategy aims to overcome acquired resistance and provide clinical benefit in several types of cancer.
Researchers identified a new role for focal adhesion kinase in producing vascular leakiness in lung tissue, increasing expression of E-selectin and attracting cancer cells. Blocking FAK activity reduced both vascular permeability and metastatic cell adhesion.
A new type of VEGFR-3 blocking antibody has been developed to inhibit angiogenesis in cancerous tumors. The antibody was shown to be effective even at high concentrations of the growth factor, and combining it with another inhibitor provided synergistic inhibition.
Two studies published in Cell Transplantation found that administering bone marrow stem cells promoted functional recovery and reduced damage after stroke, while VEGF administration provided near complete neurological protection. These findings suggest two potential treatments for stroke and could offer new recourse against its ravages.
Analyzing Spanish gene expression data may help identify patients who will benefit most from treatment with angiogenesis-inhibitor drugs. Researchers found a correlation between high levels of VEGF-A and VEGFR-1 in tumor samples and poor prognosis, suggesting these genes could be used to tailor therapy to individual patients.
The European Association of Urology Congress highlights advances in renal cell carcinoma management, including immunotherapy, targeted therapies, and angiogenesis blockers. New treatments like bevacizumab, sunitinib, sorafenib, temsirolimus, and everolimus have shown promise in stabilizing metastatic kidney cancer for a certain period.
Researchers at UMass Chan Medical School have identified a novel microRNA-mediated genetic pathway responsible for triggering vascular growth in zebrafish embryos. This discovery provides new insights into how vascular systems develop and may offer a potential therapeutic target for limiting blood vessel formation in solid cancers.
Researchers report that OSCC cells produce high levels of VEGF, promoting proliferation and invasion. A subpopulation of OSCC cells may undergo an epithelial-to-endothelial transition, facilitating tumor progression and metastases.
Researchers at Vanderbilt University Medical Center used zebrafish to identify novel compounds that selectively target bone-related diseases and cancer. By leveraging the zebrafish model, they discovered potent BMP inhibitors with improved selectivity, bypassing off-target effects.
Researchers at University of Helsinki and Paul Scherrer Institute determine crystal structure of VEGF-C ligand binding domain with its receptor complex, providing new insights into cancer cell growth and metastasis. The findings support the use of blocking VEGFs as a strategy to inhibit tumor growth.
Researchers at Georgia Tech have developed bioengineered hydrogels that induce significant vasculature growth in damaged tissue. The hydrogels release VEGF, stimulating blood vessel formation, and degrade in a controlled fashion, allowing for functional vascularization and integration with host circulatory system.
Johns Hopkins researchers found that a protein called vascular endothelial growth factor (VEGF) is responsible for the cell overgrowth in chronic rhinosinusitis with polyps. This discovery gives scientists a new target for treating this form of the disease, which typically resists current treatments.
Scientists found that a lack of diffusible VEGF causes retinal defects like geographic atrophy, which may impact the use of anti-VEGF drugs for wet macular degeneration. The study increases understanding of AMD's causes and offers potential new therapies.
Human liver cyst walls develop vascular structures, driving cell proliferation and growth. Inhibiting VEGF receptor signaling blocks angiogenesis, a promising approach to prevent liver cyst expansion in ADPKD patients.
Researchers discovered that high glucose levels in diabetic tissue lead to reduced vascular endothelial growth factor production and impaired HIF-1a function. Deferoxamine, an iron-binding drug, has been shown to improve wound healing by restoring HIF-1a-p300 interaction, leading to increased growth factor production.
Researchers have discovered a new target for the diagnosis and treatment of age-related macular degeneration by blocking the activity of the CCR3 protein. This approach shows promise as a safer and more effective alternative to current treatments, which target vascular endothelial growth factor (VEGF).
Research in mice and human stem cells identified specific new therapeutic targets for treating cancer, including a gene called Dscr1 that suppresses angiogenesis and tumor growth. The study suggests that people with Down syndrome may benefit from an extra dose of one or more cancer-protective genes.
Researchers at the University of California, San Diego, have identified a potential new treatment for retinopathy in premature infants using JNK1 inhibitors. The study found that inhibiting JNK1 reduced abnormal blood vessel growth and vision loss in mouse models of ROP.
Researchers are developing new classes of anti-androgen therapies, including MDV3100, abiraterone, and OGX-427, to treat castrate-resistant prostate cancer (CRPC). Angiogenesis inhibitors like bevacizumab target vascular endothelial growth factor (VEGF) to slow tumor growth and metastasis.
Researchers found that vascular endothelial growth factor (VEGF) and intercellular adhesion molecule (ICAM)-1 are key players in the development of diabetic macular edema (DME), a serious complication of retinopathy. The study suggests that intravitreal injection of steroids like triamcinolone acetonide may be useful in treating DME.
Researchers at VIB and NeuroNova are conducting the first trial of a potential ALS treatment, which involves administering VEGF protein directly into the cerebrospinal fluid. This innovative approach has shown promising results in animal models, with treated rats manifesting the disease later and living longer than untreated animals.
A recent study published in PLoS ONE suggests that anti-VEGF drugs used to treat macular degeneration could cause the death of photoreceptors and Muller glia cells in adult mice. The research highlights the need for caution when using these drugs, as their effects on the retina may be more complex than previously thought.
A team of researchers has discovered a mechanism for the rapid growth of infantile hemangioma, a common childhood tumor. The study found that endothelial cells, which line the blood vessels, are responsible for the tumors' growth and can be targeted with anti-VEGF therapy.
The FDA has mandated boxed warnings for COX-2 selective inhibitors and traditional NSAIDs due to their cardiovascular risks. Novel anti-VEGF therapies, such as ranibizumab and bevacizumab, may also pose cardiovascular safety concerns despite proven benefits in treating wet AMD
Blood vessel cells can be instructed to form three-dimensional, tube-like structures using a special type of 'instructor' molecule. This discovery may lead to the development of new stem cell-based therapies for organ transplantation.
Researchers found that microRNA miR-126 regulates vascular development, structure, migration, proliferation and survival of endothelial cells. The study provides clues to potential therapeutic targets for diseases impacted by the vascular system.
A recent study found that immunosuppressive drugs like cyclosporine increase the expression of vascular endothelial growth factor (VEGF), which can signal tumor growth after organ transplantation. The researchers suggest that targeting VEGF with anti-VEGF therapies may reduce cancer risk in transplant patients.
Researchers at the University of Pennsylvania School of Medicine have identified a fruit fly protein called Argos that acts as a decoy receptor to neutralize tumor growth factors. This discovery may lead to new cancer drug designs by mimicking the silent binding of growth factors, similar to existing treatments like Avastin.
Researchers discovered a correlation between syndecan-1, E-cadherin and integrins with gastric cancer prognosis. The study suggests these markers could be important indexes for predicting the outcome of gastric carcinoma patients.
Researchers suggest a novel approach to reducing VEGF-induced vision loss by targeting Src kinases, offering a potential alternative to painful eye injections. Leaky Ca2+ release channels in the brain and heart may also contribute to seizures and irregular heartbeats in individuals with certain inherited disorders.
Researchers are investigating how biomechanical forces affect blood vessel growth in the lungs of babies with congenital heart disease. The study aims to understand the mechanisms behind this phenomenon and potentially develop improved treatments for affected children.
Researchers at Schepens Eye Research Institute found that blocking VEGF can damage the cell lining preventing fluid from leaking into the brain. This may contribute to Avastin's neurological side effects in humans.
A new study reveals that Avastin's side effects may be caused by the blockage of VEGF, which normally protects brain cells from fluid leakage. In mice, this blockage led to brain swelling and cell death.
New research reveals VEGF-B's protective effects on nerve cells without inducing angiogenesis, providing new hope for treating neurodegenerative diseases. VEGF-B treatment has shown to inhibit brain cell death in mouse models of stroke and ocular neurodegenerative disorders.
Research shows depression significantly increases risk of death following a heart attack, with depressed patients more than twice as likely to die if they don't recover from depression within six months. The study also highlights the role of molecular mechanisms and inflammatory molecules in this association.
Researchers found an antibody against placental growth factor (PlGF) blocks tumor growth and enhances chemotherapy effects in mice. The antibody has a better safety profile than VEGF inhibitors, which cause severe side effects.
Researchers have successfully used RNA interference (RNAi) technology to specifically silence the vascular endothelial growth factor (VEGF) gene, a key player in tumor angiogenesis. This method shows great promise for developing targeted therapeutic approaches to inhibit VEGF expression and potentially suppress cancer growth.
Researchers found that a combined treatment with rapamycin and Gleevec significantly reduced splanchnic neovascularization and portal pressure in rats with established portal hypertension. The combination treatment was more effective than using either drug alone, suggesting a potential new approach for treating human patients.
Researchers at UCLA's Jonsson Cancer Center found that blocking angiogenesis signaling from inside endothelial cells can result in heart attacks, fatal strokes, and systemic vascular illness. The study suggests a more targeted approach to drug delivery may be necessary to minimize side effects.
The National Institute for Health and Clinical Excellence (NICE) proposes restricting use of ranibizumab and pegaptanib to patients who have gone blind in one eye. However, the Drug and Therapeutics Bulletin concludes that this approach is 'unacceptable' and calls for universal access to these sight-saving drugs. NICE has also not issu...
A Scripps Research study found that chronic methamphetamine abuse can lead to vascular inflammation and deterioration, increasing the risk of cardiovascular disease. The study also discovered that long-term methamphetamine users have aberrant immune responses, producing proinflammatory cytokines.
Axitinib produced tumor regression or stable disease in almost 75% of patients with advanced thyroid cancer, according to a phase-2 trial. The study also found that axitinib prevented tumor growth and had a favorable side effect profile.
Preliminary results of a Phase II trial show favorable outcomes for patients with recurrent epithelial ovarian cancer treated with VEGF Trap. After one month, 85% of participants showed stable disease, while 41% continued to have stable disease after fourteen weeks.
Scientists at Karolinska Institutet identified a crucial role of Dll4 in blood vessel formation through angiogenesis. The study found that Dll4 signalling determines the number of sprouts and branches formed, which is essential for tissue health and disease prevention.
A new study found that a commonly used drug to slow central vision loss can also treat diabetic retinopathy, a common complication of diabetes. The treatment showed promise in improving reading ability and reducing swelling in the retina by targeting vascular endothelial growth factor, a protein that promotes unwanted blood vessel growth.
Researchers discovered a novel 'Trojan Horse' agent, VEGF121/rGel, that completely prevented bone tumor development in 50% of mice. The agent stops specialized cells within the bone from chewing up bone material to make room for implanted tumors to grow.
Researchers have developed a manmade protein that can reverse obstructive blood vessel growth, reducing its effects on cancer, diabetic retinopathy, and macular degeneration. The protein, which targets vascular endothelial growth factor (VEGF), shows promise for treating these conditions.
A soluble form of a receptor called sflt-1 traps factors that enable growth of vision-obstructing blood vessels in the cornea. By eliminating sflt-1, researchers found that mice corneas consistently developed blood vessels.
Researchers at University of Texas Medical School identified proteins required for E. faecalis endocarditis, potentially leading to new treatment approaches. In another study, tumors induce immunosuppressive inflammatory monocytes that can blunt the anti-tumor immune response, providing new avenues for cancer therapy development.
Researchers found that patients with tumors producing high levels of VEGF and its receptor benefit most from targeted treatments. The study identified a correlation between tumor mutational analysis, VEGF expression, and treatment response.
Research reveals two proteins in blood foretell development of preeclampsia, a life-threatening complication of pregnancy. High levels of soluble endoglin and sFlt1 indicate severe forms of preeclampsia and offer hope for early detection and cure.
Researchers have identified three genetic variants associated with an increased risk of cot death, also known as SIDS. The study found that babies born with these specific variants are up to 14 times more likely to die from the condition.
Researchers identify VEGFR-3 as a key factor in preventing blood vessel growth in the cornea. The protein acts as a sink to neutralize growth factors, maintaining a blood-vessel-free cornea essential for clear vision. This discovery holds promise for treating eye disease and cancer.
A new study found that dopamine agonist cabergoline reduces hemoconcentration, ascites, and moderate to severe OHSS incidence in women at risk. The treatment could lead to better understanding of the mechanism of OHSS development and effective treatment options.
The study found that activating hedgehog signals in adult mouse hearts increased blood vessel density, offering an alternative to invasive procedures. The researchers believe a drug treatment targeting hedgehog signaling could provide substantial benefit to patients with ischemic heart disease and myocardial infarctions.